Sample sweepstakes congratulations letter

Drove 40 minutes for $5 walmart gift card.

2024.06.07 20:54 Spyro_XyX Drove 40 minutes for $5 walmart gift card.

Drove 40 minutes for $5 walmart gift card.
I got a letter in the mail from a local dealership with a sweepstakes listed at the bottom. If I brought this notice in I could either win $2500 cash $500 gas card or (up to) $500 walmart gift card I knew they were going to try to sell me a car, I'm not dumb, but I figured chatting with someone for a minute is worth one of those things, right?? Honestly they were super nice, I informed them up front I was happy with my car and the sales guy didn't try to push the issue at all, which was amazing. Then he walks away and comes back with this $5 walmart gift card, and even he looked disappointed for me. I know it said (up to) on the walmart card, but I really didnt expect 5 bucks.. I guess I should've known it would be so little, but I really got my hopes up for a little extra cash with the way things are going. 🙄
submitted by Spyro_XyX to mildlyinfuriating [link] [comments]


2024.06.07 20:52 Jealous_Tie7190 Is this job offer a scam?

I have recently completed a 6-month full stack software engineering bootcamp.I have been looking for a job and have run into a bunch of scams. I recently got an email asking me to fill out a questionnaire. I did so and received this email.
The fact that I had no real interview and that the job is offering $80 an hour and that they said they will send me a check for equipment are HUGE red flags to me. But I am desperate and would love for this to be real. Would it hurt if I provided the information they requested? Can I put a check in my bank and not cash it and see if it bounces? Will I be penalized?
"Hello Brianna,
We are pleased to extend an official offer of employment to you for the position of Web Developer (Remote) with our esteemed organization. Your extensive experience and demonstrated capabilities have led us to this decision, and we are confident that you will excel in this role as a valued member of our team.
Congratulations on your successful application! We are thrilled to welcome you to LIA, where we believe your expertise, skills, and background will greatly enhance our collective efforts and contribute significantly to the success of our company.
As part of your onboarding process, you will receive detailed instructions regarding your daily responsibilities via email. Additionally, I will be available online to provide guidance and support as you transition into your new role. Your onboarding journey will commence with a comprehensive 3 to 5-day online training session conducted via Zoom, allowing you to familiarize yourself with our processes and procedures.
The starting compensation for your position is $80 per hour, and you will have the option to receive payment on a weekly basis via check, direct deposit, or wire transfer. In addition to competitive pay, we offer a range of benefits including paid time off, a comprehensive wellness program, and health, vision, and dental insurance coverage. Furthermore, you will become eligible for additional benefits following three months of employment with us.
Upon completion of your training, you will be provided with a unique user ID, password, and access to our corporate server, along with a contact list for each department to facilitate seamless communication and collaboration.
To ensure a smooth transition, a check will be issued to cover the cost of office supplies and necessary software for setting up your workstation prior to commencing training and official duties.
Your offer letter of employment will be sent to you shortly, with the aim of expediting your onboarding process and initiating your training without delay.
In order to proceed with the necessary formalities, please promptly provide the following information to our HR department:
Please send the requested details to HR at " (i removed the email) " and kindly copy me for reference.
Once again, congratulations on your new role, and we look forward to having you on board."
submitted by Jealous_Tie7190 to Scams [link] [comments]


2024.06.07 20:25 Anaclastic Appreciation post for the current state of this subreddit

Took a looong break from this subreddit due to how unbearably toxic it had become in a polar opposite to how it started and just came back expecting to wince at a bloodbath of witch hunts in an echo chamber full of sycophants etc...
Imagine my surprise when i see some fine patriotic memes in the front page again.
May Liberty fill my sample container... theres even bombastic gameplay clips again!
My heart is full of admiration for everyone involved in helping this place retain its brilliant spirit and just straight up fun atmosphere. So let me congratulate you who have ventured unperturbed through the marsh of languishing resentment to deliver unto us the STRENGTH TO BE FREE!
submitted by Anaclastic to Helldivers [link] [comments]


2024.06.07 19:32 Tech_Rhetoric_X Hand delivering a resume

I rarely find a position within 30 minutes of where I live. A hybrid technical writing job for a medical device company is 11 miles from my house.
Should I dress in business-appropriate attire and hand deliver my resume? I may also include a relevant writing sample. I want to maintain a professional approach and avoid anything gimmicky.
Edit: I would also include a cover letter stating I applied online.
submitted by Tech_Rhetoric_X to technicalwriting [link] [comments]


2024.06.07 19:20 Temporary_Noise_4014 RenovoRx CEO Issues Update Letter to Shareholders (NASDAQ: RNXT)

RenovoRx CEO Issues Update Letter to Shareholders (NASDAQ: RNXT)

https://preview.redd.it/ipglk9e9o65d1.png?width=325&format=png&auto=webp&s=ef496929ad531bcef3f1c1d192e4c024bfcaef33
LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today provided a letter to shareholders from Chief Executive Officer, Shaun Bagai.
Dear Fellow RenovoRx Shareholders,
The first quarter of 2024 marked a significant period in our company’s evolution, and we have set the stage for significant milestones in the foreseeable future. Our team is steadfast in RenovoRx’s mission to continue on a clinical pathway towards improving patients’ lives by using our patented products to deliver precision therapies that have the potential to transform the standard of care in difficult-to-treat cancers.
With $17.2 million in gross proceeds raised since the beginning of 2024, and with a proven history of prudent stewardship of our capital resources, RenovoRx has sufficient funding to advance our pivotal Phase III TIGeR-PaC clinical trial and expand the development pipeline into additional cancer indications. Our priority remains on TIGeR-PaC in Locally Advanced Pancreatic Cancer (LAPC) first and foremost, and its progress towards a second interim readout triggered by the 52nd event (death) in the trial estimated late 2024, and ultimate completion thereafter. Additionally, we intend to pursue the expansion of our proprietary Trans-Arterial Micro-Perfusion (TAMP™) therapy platform and the clinical development of our pipeline into additional cancer indications. Lastly, we will continue to investigate our ongoing exploration of new commercial business development opportunities with our therapeutic technologies.
During the first quarter, we continued to progress the TIGeR-PaC clinical trial, an ongoing randomized multi-center study in LAPC using RenovoRx’s TAMP therapy platform to evaluate its first product candidate, RenovoGem™, a novel oncology drug-device combination product. The study is comparing treatment with TAMP to the current standard of care (systemic intravenous chemotherapy).
In tandem with the positive progress that we have made in advancing TAMP with our TIGeR-PaC study, we made important additions to our management team and Scientific Advisory Board, bolstering our strong leadership. These additions enhance our already deep expertise resident at RenovoRx.
In March, RenovoRx promoted Leesa Gentry to Chief Clinical Officer and Ronald B. Kocak to Principal Accounting Officer. These promotions reflect our commitment to assembling a dynamic team poised to continue to lead a successful clinical pathway for our proprietary therapy platform. We have streamlined our team, focusing our efforts on strategic initiatives to drive growth and innovation. On behalf of our Board of Directors, I extend our gratitude to Leesa and Ron for their hard work and dedication to date and congratulate them on their well-deserved promotions.
In March, important research studies were published supporting the TAMP therapy platform, including:
  • A publication of pre-clinical studies supporting the efficacy and drug-delivery mechanism potential of TAMP to improve targeted cancer drug treatment delivery was published in the peer-reviewed Journal of Vascular Interventional Radiology. The manuscript was authored by Khashayar Farsad, MD, PhD of the Department of Interventional Radiology at Oregon Health and Science University, and co-authored by Paula M. Novelli, MD, of the University of Pittsburgh Hillman Cancer Center, together with other researchers, including RenovoRx’s Chief Medical Officer, Ramtin Agah, MD. View press release.
  • David Sperling, MD, Associate Professor of Radiology at Columbia University Irving Medical Center in New York, presented a clinical data abstract at the recent 2024 Society of Interventional Radiology Annual Scientific Meeting. The abstract highlighted a sub-study of the TIGeR-PaC clinical trial and featured important data to assist in optimization of TAMP with better risk stratification of patients while improving guidance of TAMP therapy for LAPC treatment. It is important to understand appropriate candidates for TAMP, and managing patients who could be at any risk is paramount to helping underserved patient populations, like those diagnosed with LAPC. This is especially important given the potential of the TAMP therapy platform. View press release.
The first interim analysis in the Phase III clinical trial was completed in March 2023, with the Data Monitoring Committee recommending a continuation of the study. The TIGeR-PaC study is investigating TAMP in LAPC. The study's primary endpoint is a 6-month Overall Survival benefit with secondary endpoints including reduced side effects versus standard of care. We are expecting the clinical events necessary for a second interim analysis should take place by the end of this year, and we are eagerly anticipating the outcome of this analysis.
In closing, I want to extend our appreciation to our clinical sites and patients in our Phase III clinical trial, along with our long-term and newer shareholders. With your support, our team is very well positioned to continue its commitment to improving patients’ lives and lifespans by delivering precision therapies that have the potential to revolutionize the current paradigm of cancer care. Your trust and confidence in RenovoRx have helped us build the remarkable company we have become, and one whose future has never been brighter.
We encourage anyone interested to visit our website, renovorx.com, to learn more, and email us at [renovorx@kcsa.com](mailto:renovorx@kcsa.com) to contact us.
Sincerely, Shaun R. Bagai, CEO RenovoRx, Inc. (NASDAQ: RNXT)
About RenovoRx, Inc.
RenovoRx is a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug delivery platform for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. RenovoRx’s novel and patented approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy. Our Phase III lead product candidate, RenovoGem™, a novel oncology drug-device combination product, is being investigated under a U.S. investigational new drug application that is regulated by the FDA’s 21 CFR 312 pathway. RenovoGem is currently being evaluated for the treatment of locally advanced pancreatic cancer by the Center for Drug Evaluation and Research (the drug division of FDA).
RenovoRx is committed to transforming the lives of patients by delivering innovative solutions to change the current paradigm of cancer care. RenovoGem is currently under investigation for TAMP therapeutic delivery of gemcitabine and has not been approved for commercial sale.
For more information, visit www.renovorx.com. Follow RenovoRx on Facebook, LinkedIn, and Twitter.
submitted by Temporary_Noise_4014 to StonkFeed [link] [comments]


2024.06.07 19:19 Temporary_Noise_4014 RenovoRx CEO Issues Update Letter to Shareholders (NASDAQ: RNXT)

RenovoRx CEO Issues Update Letter to Shareholders (NASDAQ: RNXT)

https://preview.redd.it/hqh65yz7o65d1.png?width=325&format=png&auto=webp&s=4f057b0384d87ccaa071d84c10ffff85b0299ae2
LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today provided a letter to shareholders from Chief Executive Officer, Shaun Bagai.
Dear Fellow RenovoRx Shareholders,
The first quarter of 2024 marked a significant period in our company’s evolution, and we have set the stage for significant milestones in the foreseeable future. Our team is steadfast in RenovoRx’s mission to continue on a clinical pathway towards improving patients’ lives by using our patented products to deliver precision therapies that have the potential to transform the standard of care in difficult-to-treat cancers.
With $17.2 million in gross proceeds raised since the beginning of 2024, and with a proven history of prudent stewardship of our capital resources, RenovoRx has sufficient funding to advance our pivotal Phase III TIGeR-PaC clinical trial and expand the development pipeline into additional cancer indications. Our priority remains on TIGeR-PaC in Locally Advanced Pancreatic Cancer (LAPC) first and foremost, and its progress towards a second interim readout triggered by the 52nd event (death) in the trial estimated late 2024, and ultimate completion thereafter. Additionally, we intend to pursue the expansion of our proprietary Trans-Arterial Micro-Perfusion (TAMP™) therapy platform and the clinical development of our pipeline into additional cancer indications. Lastly, we will continue to investigate our ongoing exploration of new commercial business development opportunities with our therapeutic technologies.
During the first quarter, we continued to progress the TIGeR-PaC clinical trial, an ongoing randomized multi-center study in LAPC using RenovoRx’s TAMP therapy platform to evaluate its first product candidate, RenovoGem™, a novel oncology drug-device combination product. The study is comparing treatment with TAMP to the current standard of care (systemic intravenous chemotherapy).
In tandem with the positive progress that we have made in advancing TAMP with our TIGeR-PaC study, we made important additions to our management team and Scientific Advisory Board, bolstering our strong leadership. These additions enhance our already deep expertise resident at RenovoRx.
In March, RenovoRx promoted Leesa Gentry to Chief Clinical Officer and Ronald B. Kocak to Principal Accounting Officer. These promotions reflect our commitment to assembling a dynamic team poised to continue to lead a successful clinical pathway for our proprietary therapy platform. We have streamlined our team, focusing our efforts on strategic initiatives to drive growth and innovation. On behalf of our Board of Directors, I extend our gratitude to Leesa and Ron for their hard work and dedication to date and congratulate them on their well-deserved promotions.
In March, important research studies were published supporting the TAMP therapy platform, including:
  • A publication of pre-clinical studies supporting the efficacy and drug-delivery mechanism potential of TAMP to improve targeted cancer drug treatment delivery was published in the peer-reviewed Journal of Vascular Interventional Radiology. The manuscript was authored by Khashayar Farsad, MD, PhD of the Department of Interventional Radiology at Oregon Health and Science University, and co-authored by Paula M. Novelli, MD, of the University of Pittsburgh Hillman Cancer Center, together with other researchers, including RenovoRx’s Chief Medical Officer, Ramtin Agah, MD. View press release.
  • David Sperling, MD, Associate Professor of Radiology at Columbia University Irving Medical Center in New York, presented a clinical data abstract at the recent 2024 Society of Interventional Radiology Annual Scientific Meeting. The abstract highlighted a sub-study of the TIGeR-PaC clinical trial and featured important data to assist in optimization of TAMP with better risk stratification of patients while improving guidance of TAMP therapy for LAPC treatment. It is important to understand appropriate candidates for TAMP, and managing patients who could be at any risk is paramount to helping underserved patient populations, like those diagnosed with LAPC. This is especially important given the potential of the TAMP therapy platform. View press release.
The first interim analysis in the Phase III clinical trial was completed in March 2023, with the Data Monitoring Committee recommending a continuation of the study. The TIGeR-PaC study is investigating TAMP in LAPC. The study's primary endpoint is a 6-month Overall Survival benefit with secondary endpoints including reduced side effects versus standard of care. We are expecting the clinical events necessary for a second interim analysis should take place by the end of this year, and we are eagerly anticipating the outcome of this analysis.
In closing, I want to extend our appreciation to our clinical sites and patients in our Phase III clinical trial, along with our long-term and newer shareholders. With your support, our team is very well positioned to continue its commitment to improving patients’ lives and lifespans by delivering precision therapies that have the potential to revolutionize the current paradigm of cancer care. Your trust and confidence in RenovoRx have helped us build the remarkable company we have become, and one whose future has never been brighter.
We encourage anyone interested to visit our website, renovorx.com, to learn more, and email us at [renovorx@kcsa.com](mailto:renovorx@kcsa.com) to contact us.
Sincerely, Shaun R. Bagai, CEO RenovoRx, Inc. (NASDAQ: RNXT)
About RenovoRx, Inc.
RenovoRx is a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug delivery platform for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. RenovoRx’s novel and patented approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy. Our Phase III lead product candidate, RenovoGem™, a novel oncology drug-device combination product, is being investigated under a U.S. investigational new drug application that is regulated by the FDA’s 21 CFR 312 pathway. RenovoGem is currently being evaluated for the treatment of locally advanced pancreatic cancer by the Center for Drug Evaluation and Research (the drug division of FDA).
RenovoRx is committed to transforming the lives of patients by delivering innovative solutions to change the current paradigm of cancer care. RenovoGem is currently under investigation for TAMP therapeutic delivery of gemcitabine and has not been approved for commercial sale.
For more information, visit www.renovorx.com. Follow RenovoRx on Facebook, LinkedIn, and Twitter.
submitted by Temporary_Noise_4014 to SmallCapStocks [link] [comments]


2024.06.07 19:19 Temporary_Noise_4014 RenovoRx CEO Issues Update Letter to Shareholders (NASDAQ: RNXT)

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today provided a letter to shareholders from Chief Executive Officer, Shaun Bagai. Dear Fellow RenovoRx Shareholders, The first quarter of 2024 marked a significant period in our company’s evolution, and we have set the stage for significant milestones in the foreseeable future. Our team is steadfast in RenovoRx’s mission to continue on a clinical pathway towards improving patients’ lives by using our patented products to deliver precision therapies that have the potential to transform the standard of care in difficult-to-treat cancers. With $17.2 million in gross proceeds raised since the beginning of 2024, and with a proven history of prudent stewardship of our capital resources, RenovoRx has sufficient funding to advance our pivotal Phase III TIGeR-PaC clinical trial and expand the development pipeline into additional cancer indications. Our priority remains on TIGeR-PaC in Locally Advanced Pancreatic Cancer (LAPC) first and foremost, and its progress towards a second interim readout triggered by the 52nd event (death) in the trial estimated late 2024, and ultimate completion thereafter. Additionally, we intend to pursue the expansion of our proprietary Trans-Arterial Micro-Perfusion (TAMP™) therapy platform and the clinical development of our pipeline into additional cancer indications. Lastly, we will continue to investigate our ongoing exploration of new commercial business development opportunities with our therapeutic technologies. During the first quarter, we continued to progress the TIGeR-PaC clinical trial, an ongoing randomized multi-center study in LAPC using RenovoRx’s TAMP therapy platform to evaluate its first product candidate, RenovoGem™, a novel oncology drug-device combination product. The study is comparing treatment with TAMP to the current standard of care (systemic intravenous chemotherapy). In tandem with the positive progress that we have made in advancing TAMP with our TIGeR-PaC study, we made important additions to our management team and Scientific Advisory Board, bolstering our strong leadership. These additions enhance our already deep expertise resident at RenovoRx. In March, RenovoRx promoted Leesa Gentry to Chief Clinical Officer and Ronald B. Kocak to Principal Accounting Officer. These promotions reflect our commitment to assembling a dynamic team poised to continue to lead a successful clinical pathway for our proprietary therapy platform. We have streamlined our team, focusing our efforts on strategic initiatives to drive growth and innovation. On behalf of our Board of Directors, I extend our gratitude to Leesa and Ron for their hard work and dedication to date and congratulate them on their well-deserved promotions. In March, important research studies were published supporting the TAMP therapy platform, including: A publication of pre-clinical studies supporting the efficacy and drug-delivery mechanism potential of TAMP to improve targeted cancer drug treatment delivery was published in the peer-reviewed Journal of Vascular Interventional Radiology. The manuscript was authored by Khashayar Farsad, MD, PhD of the Department of Interventional Radiology at Oregon Health and Science University, and co-authored by Paula M. Novelli, MD, of the University of Pittsburgh Hillman Cancer Center, together with other researchers, including RenovoRx’s Chief Medical Officer, Ramtin Agah, MD. View press release. David Sperling, MD, Associate Professor of Radiology at Columbia University Irving Medical Center in New York, presented a clinical data abstract at the recent 2024 Society of Interventional Radiology Annual Scientific Meeting. The abstract highlighted a sub-study of the TIGeR-PaC clinical trial and featured important data to assist in optimization of TAMP with better risk stratification of patients while improving guidance of TAMP therapy for LAPC treatment. It is important to understand appropriate candidates for TAMP, and managing patients who could be at any risk is paramount to helping underserved patient populations, like those diagnosed with LAPC. This is especially important given the potential of the TAMP therapy platform. View press release. The first interim analysis in the Phase III clinical trial was completed in March 2023, with the Data Monitoring Committee recommending a continuation of the study. The TIGeR-PaC study is investigating TAMP in LAPC. The study's primary endpoint is a 6-month Overall Survival benefit with secondary endpoints including reduced side effects versus standard of care. We are expecting the clinical events necessary for a second interim analysis should take place by the end of this year, and we are eagerly anticipating the outcome of this analysis. In closing, I want to extend our appreciation to our clinical sites and patients in our Phase III clinical trial, along with our long-term and newer shareholders. With your support, our team is very well positioned to continue its commitment to improving patients’ lives and lifespans by delivering precision therapies that have the potential to revolutionize the current paradigm of cancer care. Your trust and confidence in RenovoRx have helped us build the remarkable company we have become, and one whose future has never been brighter. We encourage anyone interested to visit our website, renovorx.com, to learn more, and email us at renovorx@kcsa.com to contact us. Sincerely, Shaun R. Bagai, CEO RenovoRx, Inc. (NASDAQ: RNXT) About RenovoRx, Inc. RenovoRx is a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug delivery platform for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. RenovoRx’s novel and patented approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy. Our Phase III lead product candidate, RenovoGem™, a novel oncology drug-device combination product, is being investigated under a U.S. investigational new drug application that is regulated by the FDA’s 21 CFR 312 pathway. RenovoGem is currently being evaluated for the treatment of locally advanced pancreatic cancer by the Center for Drug Evaluation and Research (the drug division of FDA). RenovoRx is committed to transforming the lives of patients by delivering innovative solutions to change the current paradigm of cancer care. RenovoGem is currently under investigation for TAMP therapeutic delivery of gemcitabine and has not been approved for commercial sale. For more information, visit www.renovorx.com. Follow RenovoRx on Facebook, LinkedIn, and Twitter.
submitted by Temporary_Noise_4014 to Penny_Stocks [link] [comments]


2024.06.07 19:19 Temporary_Noise_4014 RenovoRx CEO Issues Update Letter to Shareholders (NASDAQ: RNXT)

RenovoRx CEO Issues Update Letter to Shareholders (NASDAQ: RNXT)

https://preview.redd.it/t3fxd7x4o65d1.png?width=325&format=png&auto=webp&s=44b4e25004d012024d73aca01acadf167fdc02e6
LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today provided a letter to shareholders from Chief Executive Officer, Shaun Bagai.
Dear Fellow RenovoRx Shareholders,
The first quarter of 2024 marked a significant period in our company’s evolution, and we have set the stage for significant milestones in the foreseeable future. Our team is steadfast in RenovoRx’s mission to continue on a clinical pathway towards improving patients’ lives by using our patented products to deliver precision therapies that have the potential to transform the standard of care in difficult-to-treat cancers.
With $17.2 million in gross proceeds raised since the beginning of 2024, and with a proven history of prudent stewardship of our capital resources, RenovoRx has sufficient funding to advance our pivotal Phase III TIGeR-PaC clinical trial and expand the development pipeline into additional cancer indications. Our priority remains on TIGeR-PaC in Locally Advanced Pancreatic Cancer (LAPC) first and foremost, and its progress towards a second interim readout triggered by the 52nd event (death) in the trial estimated late 2024, and ultimate completion thereafter. Additionally, we intend to pursue the expansion of our proprietary Trans-Arterial Micro-Perfusion (TAMP™) therapy platform and the clinical development of our pipeline into additional cancer indications. Lastly, we will continue to investigate our ongoing exploration of new commercial business development opportunities with our therapeutic technologies.
During the first quarter, we continued to progress the TIGeR-PaC clinical trial, an ongoing randomized multi-center study in LAPC using RenovoRx’s TAMP therapy platform to evaluate its first product candidate, RenovoGem™, a novel oncology drug-device combination product. The study is comparing treatment with TAMP to the current standard of care (systemic intravenous chemotherapy).
In tandem with the positive progress that we have made in advancing TAMP with our TIGeR-PaC study, we made important additions to our management team and Scientific Advisory Board, bolstering our strong leadership. These additions enhance our already deep expertise resident at RenovoRx.
In March, RenovoRx promoted Leesa Gentry to Chief Clinical Officer and Ronald B. Kocak to Principal Accounting Officer. These promotions reflect our commitment to assembling a dynamic team poised to continue to lead a successful clinical pathway for our proprietary therapy platform. We have streamlined our team, focusing our efforts on strategic initiatives to drive growth and innovation. On behalf of our Board of Directors, I extend our gratitude to Leesa and Ron for their hard work and dedication to date and congratulate them on their well-deserved promotions.
In March, important research studies were published supporting the TAMP therapy platform, including:
  • A publication of pre-clinical studies supporting the efficacy and drug-delivery mechanism potential of TAMP to improve targeted cancer drug treatment delivery was published in the peer-reviewed Journal of Vascular Interventional Radiology. The manuscript was authored by Khashayar Farsad, MD, PhD of the Department of Interventional Radiology at Oregon Health and Science University, and co-authored by Paula M. Novelli, MD, of the University of Pittsburgh Hillman Cancer Center, together with other researchers, including RenovoRx’s Chief Medical Officer, Ramtin Agah, MD. View press release.
  • David Sperling, MD, Associate Professor of Radiology at Columbia University Irving Medical Center in New York, presented a clinical data abstract at the recent 2024 Society of Interventional Radiology Annual Scientific Meeting. The abstract highlighted a sub-study of the TIGeR-PaC clinical trial and featured important data to assist in optimization of TAMP with better risk stratification of patients while improving guidance of TAMP therapy for LAPC treatment. It is important to understand appropriate candidates for TAMP, and managing patients who could be at any risk is paramount to helping underserved patient populations, like those diagnosed with LAPC. This is especially important given the potential of the TAMP therapy platform. View press release.
The first interim analysis in the Phase III clinical trial was completed in March 2023, with the Data Monitoring Committee recommending a continuation of the study. The TIGeR-PaC study is investigating TAMP in LAPC. The study's primary endpoint is a 6-month Overall Survival benefit with secondary endpoints including reduced side effects versus standard of care. We are expecting the clinical events necessary for a second interim analysis should take place by the end of this year, and we are eagerly anticipating the outcome of this analysis.
In closing, I want to extend our appreciation to our clinical sites and patients in our Phase III clinical trial, along with our long-term and newer shareholders. With your support, our team is very well positioned to continue its commitment to improving patients’ lives and lifespans by delivering precision therapies that have the potential to revolutionize the current paradigm of cancer care. Your trust and confidence in RenovoRx have helped us build the remarkable company we have become, and one whose future has never been brighter.
We encourage anyone interested to visit our website, renovorx.com, to learn more, and email us at [renovorx@kcsa.com](mailto:renovorx@kcsa.com) to contact us.
Sincerely, Shaun R. Bagai, CEO RenovoRx, Inc. (NASDAQ: RNXT)
About RenovoRx, Inc.
RenovoRx is a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug delivery platform for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. RenovoRx’s novel and patented approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy. Our Phase III lead product candidate, RenovoGem™, a novel oncology drug-device combination product, is being investigated under a U.S. investigational new drug application that is regulated by the FDA’s 21 CFR 312 pathway. RenovoGem is currently being evaluated for the treatment of locally advanced pancreatic cancer by the Center for Drug Evaluation and Research (the drug division of FDA).
RenovoRx is committed to transforming the lives of patients by delivering innovative solutions to change the current paradigm of cancer care. RenovoGem is currently under investigation for TAMP therapeutic delivery of gemcitabine and has not been approved for commercial sale.
For more information, visit www.renovorx.com. Follow RenovoRx on Facebook, LinkedIn, and Twitter.
submitted by Temporary_Noise_4014 to CanadaStocks [link] [comments]


2024.06.07 18:57 Cam_Casey [QCrit] YA Fantasy Adventure, PERSEPHONE'S PROPHECIES, 75K, 1st attempt.

Hello,
The query had 281 words in total before the manuscript sample.
I am lost on the agent personalization, Bio, and comparables.
I have no connections to anyone, and any personalization I can conceive of would be a cookie cutter sentence that I imagine would go something like this: “I have contacted you because I reached your letter of the alphabet on querytracker and it said you are open for submissions in the genre I wrote.”
I also have no Bio because I haven't done anything and I am nobody. Should I leave it as nothing, or should I at least put something like: “I am from [country] and I have a bachelors of business administration degree.” I have no comparables.
The inspiration was any story I’ve read or watched that had a prophecy, and how the prophecy's existence only makes sense if there is someone behind the scenes trying to manipulate things and impact character’s actions. (Game of Thrones, Dune, Harry Potter, and Wheel of Time are the ones that come to mind, but I am certain there are others that escape me at the moment. All of these are too big to be compared to.)
Can I get away with not listing any comparables, or should I look for books with similar themes that aren’t too famous, read them, then compare them to my book?
Thank you:
Dear [Agent],
Seventeen-year-old Persephone Trout is an oracle gifted with glimpses into the future, but to her it is more like a curse. When a witch and her companions come to town chasing prophecy, Persephone is compelled to save them from imminent dangers that only she is aware of. The witch rewards this kindness by kidnapping her and forcing Persephone to act as their guide in pursuit of a sword of legend. They are not the only seekers, however, and now danger lurks behind as well as ahead.
Persephone’s attempts to escape the witch go poorly, and dangerous desert wildlife force them all underground. With no prospects of escape, Persephone is forced to accept her situation and they soon find themselves within ancient ruins confronted by a djinn promising wishes. Persephone is the only one who recognises the dangers in the offer, but her captors do not heed her caution and collectively make three wishes, trapping themselves into the djinn’s nefarious agenda, but even Persephone could not have foreseen the djinn granting a fourth, illspoken wish.
Still in search of the sword and harried from behind, they continue forward into a trial devised by the gods to test their worthiness, and Persephone comes to realize the dangers not only to herself, but to the entire realm. She must decide how far she is willing to get involved in this prophecy, or if she can abandon it altogether and simply resume her quiet life as a small town oracle.
PERSEPHONE’S PROPHECIES, YA fantasy/adventure complete at 75,000 words is book one of a planned trilogy. A lighthearted coming of age story exploring the concepts of determinism, free will, and personal responsibility.
First 300 words:
Persephone jiggled her crystal ball, careful to not get shocked while agitating the lightning bug within, prompting spurts of yellow to ripple across the uneven surface. Her client dropped his jaw, sufficiently entranced, but Seph didn’t stop there. She swirled an incense stick slowly back and forth, a thin line of smoke trailing as if the air itself was her parchment. A few traces above flickering candles was more than enough for this particular client.
“Ah yes,” she mused softly and mysteriously. “I see it now, yes…”
Her client pulled his legs under himself, kneeling in his seat now and leaning so far forward his nose nearly touched the crystal ball.
“What?” he breathed. “What do you see?”
Persephone lowered her head to match his eye level and whispered, forcing her client to strain his ears. “To acquire the strength you seek, to become what you most desire, you must…” she let the words linger.
“I must what?” her client breathed, lip trembling.
“You must…” she paused before swiping her hand through the lines of smoke, eddies swirling in her wake as she slapped the top of the crystal ball. The smack was beautifully loud, and her client nearly leapt out of his chair. The lightning bug raged, and Persephone finished her telling with booming command. “You must eat your vegetables!”
Her client collapsed back into his chair and wailed, hands to his face.
“I told you honey,” his mother said, stepping in from the dark edges of the telling room. “Now will you stop being so fussy?”
The boy leapt to his feet, standing on the edge of the chair now to hover over the crystal ball. “Are you sure that's what it says? You promise?” he pleaded, hoping against hope there was a better way.
submitted by Cam_Casey to PubTips [link] [comments]


2024.06.07 18:13 Structure_Remarkable Split

Its weird when friend groups split up. It can be sudden or maybe this was happening all along. After 'TnT' got married Rae got weird, so I got weird, and Devin... Well he's kinda always fine. Over the past year though us 24 year olds I guess got tired of highschool and college friends. I haven't spoken to any of them for a couple months except for Devin. Not super fun to hang out with a dissolving marriage that just begun, the girl ruining that marriage (who I also happen to want her to ruin me), and Devin. Tonight I guess was just the perfect night for the other shoe to drop.
Dinner was cooking, crackling in oil over the stovetop. Meat. Searing chunks of steak with peppers, the aroma of heat, onions, and warm flesh. I shuffle it around with a wooden spoon admiring my handiwork. Well-seasoned with chili powder, dried red pepper flakes, salt, and pepper it truly was one of my best dishes since moving to this apartment. I at least would be done before 7 pm this time.
zzzzzZZZZZt zzzzzzZZZZZt…. zzzzzZZZZZt zzzzzZZZZZt
I look over to my phone, “6:30 really?” Unknown number, I let it vibrate for a second grabbing my pot and a can of refried beans. It buzzes for a 3rd time, fine. Clicking it to speaker I fiddle with the bean can, old ass can opener can’t seem to stay in.
“Hello?”
Hello is this _______?
“Yes, who is this?” I bonk the can with the opener as if the violent bonk would make it work properly. The voice on the other end seemed hesitant.
Have you seen Rae?”
“What? Wait is this Tammy?” I rolled my eyes. Great, two dull things to handle now. The lid won't budge, letting a small puff of air from my nose I aim the can opener for just under the lid. The sweet spot between the squishy side dish and sharp metal.
“Listen if this is about Trevor and Rae I don’t know anything-” The lid slightly moves up, I poke an index finger under to keep it up.
The cops came over today, have you seen Rae” Tammy was a lot less composed this time around, she's never been one for much critical thinking. This is bad. I pause my can-opening project.
“What?”
“She didn’t go to work at all this week they said, they’re gonna check her apartment tonight.” Hysterical sobs came through the speaker. “Trev and Devin both said no and I said no so if you don’t know then what if-” Not good, pregnancy didn’t help Tammy with her big heart, or her leaping to conclusions.
“T, I don’t think anything could’ve happened to her. She probably just went off somewhere for break.”
Do medical students get bre-get breaks?” Tammy sniffled, the idea of simple miscommunication never crossed her mind. “I mean probably? Didn’t Trevor get breaks for his masters?” “.. yeah he did.” Shame seemed to fill her voice. “Hey yknow how about you and Trevor come over tonight?” “Oh no I can’t, we can’t I mean. Lots to do before Bee gets here” “Oh finally picked?” “Just the starting letter, Trevor picked out a boy name though” “Lakc of enthusiasm there, it can’t be that bad can it?”
Brad” I laugh a bit as my phone vibrated to life again, this time it was the local police department. Fuck. “Wow that is ...wow, listen I’ll call you tomorrow morning ok?”
Another small sniff from Tammy’s end “Ok. Talk to you then?” “I promise, I’ll add this number to my phone right now.” That seemed to be a good enough promise as Tammy hung up immediately after. zzzzzZZZZZt zzzzzZZZZZt
Switching calls I turn my attention back to the bean can. Finger and can opener under it slowly lifting.
“Hello?” my eyes locked on my own hands as the cop on the other side explained that they were wondering if I had heard from Rae. Simple answer, no. They asked if they could come over to my house tonight. Sure, odd but ok. Nothing bad could’ve happened within the span of a call right.
“Do you know of anyone who would want to harm Rae?”
SLICE.
I pull my right hand away from the can, there's a slight slit with big wet red beads slowly oozing from it. “No No I’m fine I just gasp” The lid was oddly clean, the can was undefeated, and nothing in the world had changed at all. Except for my spilled blood, and that Rae was no longer in it at all.
“I just cut myself while cooking, I think I’ll have to call you back.” “What was tha-” I hung up. I breathed in deeply and ran over to my bathroom grabbing the handtowel and turning on the sink. I shoved my index finger under the cold water and hissed in the air with fear. It's too deep. Pink and swirly flesh revealed just underneath my skin. Too deep. I tensed my legs and pulled my hand out of the water and into the towel. The blood seemed to immediately come back. I held my index finger above my head with my other hand wrapped tight around it. I turned off the stove, grabbed my keys then left for urgent care. After a bit of novocaine in my finger and 3 stitches, I got to go back home.
There were no cops when I got home and everything is really quiet. Still smells like meat. I put dinner away for tonight and turn on the tv. Local news at 9 pm, her apartment building. The header read Grad student gore. “Unidentified flesh samples will be tested at the Loraine forensics lab, police refuse to say what specifically was at the scene. Onlookers claim to have witnessed police running out of the young womans room vomiting or dazed. What type of crime has shaken them to their core? More on that later. Jennifer?” “Thank you Megan. Our condolences to the family of the missing victim, we hope there will be answers for Rae.”
I don’t think I can try to look up the news tonight.
submitted by Structure_Remarkable to nosleep [link] [comments]


2024.06.07 18:08 -Fauste- TCG Designers React to YOUR Sorcery Cards: Sorcery Spells Community Card Design Challenge

TCG Designers React to YOUR Sorcery Cards: Sorcery Spells Community Card Design Challenge
Sorcery TCG Designers Mike, Sean, and Rafa share their favorite picks from the Sorcery: Contested Realm Design-A-Card Contest.
Get to know the design team and hear their thoughts on the community designs submitted in the Sorcery Facebook Group!
Congratulations to the 6 winners who will receive a blank Spellbook sample card!
https://youtu.be/DF30PWBzOfc
submitted by -Fauste- to SorceryTCG [link] [comments]


2024.06.07 17:54 Plane-Explorer-4458 [F4A playing M] Love and what not

Imagery. Derived not from visuals but bursting into life with every flick of the eye across words. Proses blue, pink and purple, with love and danger and challenge infused in the lettering. Heroics and braver romances, quests and daring ambitions abound, there's nothing that I enjoy more than a beautifully crafted story.
Greetings!
I am a 26 year old woman with an obsessive need to imagine, create, write and repeat. I have been seeking for inspiration to sit down and write for fsr too long, to bring those beautiful musings to pen and paper, or in this case, the screen, and nothing can be more motivating than a roleplay.
What do I offer? - A whole wide world of ideas, plots, imaginations, the scope to ramble, the freedom to toss ideas into the dark and hope the arrows catch something. I offer all creative liberties and am a huge nuisance to my characters, they never catch a break lol.
What I require in a partner? - Creativity. Join me in my ramblings and in my need to torture our characters. Let's collaborate and create, so what we have becomes a beautiful world full of twists and turns. I am a lover of world building, please join me in my enthusiasm for it.
Basic Plot ideas - High fantasy conflict/political, wars - Regency Romances (yes, I mean Bridgerton) - Cyberpunk rebellions - Model x designer (obsessive artist trope) - Upside down
Canon characters that I am looking for: - Draco Malfoy - Anthony Bridgerton
submitted by Plane-Explorer-4458 to AdvLiterateRP [link] [comments]


2024.06.07 17:43 wyem This week in AI - all the Major AI developments in a nutshell

  1. Alibaba Cloud released Qwen2 series of open models in 5 sizes: 0.5B, 1.5B, 7B, 57B-14B (MoE), 72B trained on data in 29 languages. Qwen2-72B outperforms Llama-3-70B and surpasses the performance of its predecessor, Qwen1.5-110B, despite having fewer parameters. Released under Apache 2.0 except 72B version that still uses the original Qianwen License [Details].
  2. China’s Kuaishou Technology unveiled its text-to-video model Kling that can generate 1080p high-definition videos lasting up to 2 minutes. The model is capable of producing large-scale realistic motions and simulating physical world characteristics [Details Demo videos].
  3. Stability AI released Stable Audio Open, an open source text-to-audio model for generating up to 47 seconds of audio samples and sound effects. It can generate drum beats, instrument riffs, ambient sounds, foley recordings and other audio samples for music production and sound design [Details].
  4. Researchers have used AI to identify nearly one million potential antibiotic compounds from microbial genetic data, marking a significant breakthrough in combating drug-resistant superbugs. Discovering a new antibiotic using conventional methods typically takes about 10 to 15 years [Details].
  5. Udio has added ‘audio uploads’, a new experimental feature to their AI music generation tool. You can upload an audio clip of your choice, and extend this clip either forward or backward by 32 seconds using up to 2 minutes of context [Details].
  6. Two authors of the Stanford Llama3-V team apologized to the Chinese team behind the MiniCPM-Llama3-V 2.5 open-source model, announcing they would withdraw the Llama3-V model from use amidst allegations of plagiarism on social media [Details].
  7. Nvidia shared demo of Project G-Assist - an RTX-powered AI assistant that provides context-aware help for PC games and apps. In addition to in-game assistance, it can share useful system information, configure settings to increase performance and power efficiency, and more [Video Link].
  8. Meta AI researchers introduced No Language Left Behind (NLLB), a single massively multilingual model capable of delivering high-quality translations directly between 200 languages, including the low-resource languages [Details].
  9. Nomic AI released Nomic-Embed-Vision, an open vision embedding model. Any vector created using Nomic-Embed-Text can be used to query vectors created by Nomic-Embed-Vision, and vice versa. The unified multimodal latent space outperforms the modality specific latent spaces of models like OpenAI Clip and OpenAI Text Embedding 3 Small, and making it the first open weights model to do so [Details].
  10. Mistral AI announced Mistral AI fine-tuning API as well as an open-source fine-tuning SDK for Mistral models [Details].
  11. Eleven Labs launched Text to Sound Effects tool. Their new AI Audio model can generate sound effects, short instrumental tracks and soundscapes from a text prompt [Details].
  12. Artificial Analysis launched Artificial Analysis Text to Image Model Leaderboard, to compare the quality of image models. You can take part in the Text to Image Arena, and get your personalized model ranking after 30 votes [Details]
  13. SkyworkAI released Skywork-MoE, a mixture-of-experts (MoE) model with 146 billion parameters, 16 experts, and 22 billion activated parameters. This model is initialized from the pre-existing dense Skywork-13B model. Skywork-MoE shows comparable or superior performance to models with more parameters or more activated parameters, such as Grok-1, DBRX, Mistral 8*22, and Deepseek-V2 [Details].
  14. Nvidia and Hugging Face are partnering to simplify generative AI model deployments. The dedicated NIM endpoint spins up cloud instances, fetches Nvidia-optimized models, and enables inference with just a few clicks [Details].
  15. Firefox 130 will introduce an experimental new capability to automatically generate alt-text for images using a fully private on-device AI model. The feature will be available as part of Firefox’s built-in PDF editor [Details].
  16. Microsoft Research introduced Aurora, a large-scale foundation model of the atmosphere trained on over a million hours of diverse weather and climate data. In under a minute, Aurora produces 5-day global air pollution predictions and 10-day high-resolution weather forecasts that outperform state-of-the-art classical simulation tools and the best specialized deep learning models [Details].
  17. Stability AI officially announced the open release date of Stable Diffusion 3 Medium for June 12th. Signup for the wait list here [Link].
  18. OpenAI shared their research work towards understanding the neural activity of language models and released a full suite of autoencoders for GPT-2 small, along with code for using them, and the feature visualizer to get a sense of what the GPT-2 and GPT-4 features may correspond to [Details]
  19. Together AI released Dragonfly, a set of vision-language models based on a new architecture that enhances fine-grained visual understanding and reasoning about image regions. Two new open-source models released: Llama-3-8b-Dragonfly-v1 a general-domain model trained on 5.5 million image-instruction pairs and Llama-3-8b-Dragonfly-Med-v1 finetuned on additional 1.4 biomedical image-instruction data [Details].
  20. Mamba 2, the next version of Mamba state space model has been released. Researchers shared the new architecture details in this blog post [GitHub].
  21. Mozilla has launched the 2024 Builders Accelerator offering up to $100,000 in funding for projects that advance open source AI, with a focus on Local AI solutions [Details].
  22. Current and former employees of major AI companies have published an open letter ‘A Right to Warn about Advanced Artificial Intelligence’, advocating for stronger protections and transparency measures to enable safe disclosure of AI-related risks without fear of retaliation [Details]
  23. Google updated its AI Overviews in Search, addressing issues with erroneous and fake information [Details].
  24. Amazon’s Project PI, or ‘Private Investigator,’ setup combines generative AI and computer vision to ‘see’ damage on products or determine if they are the wrong color or size before the item gets sent to customers [Details].
  25. Nvidia CEO Jensen Huang introduced the company's next-generation AI-accelerating GPU platform, “Rubin“ expected in 2026 [Details].
Source: AI Brews - Links removed from this post due to auto-delete, but they are present in the newsletter. it's free to join, sent only once a week with bite-sized news, learning resources and selected tools. Thanks!
submitted by wyem to ArtificialInteligence [link] [comments]


2024.06.07 17:28 wyem This week in AI - all the Major AI developments in a nutshell

  1. Alibaba Cloud released Qwen2 series of open models in 5 sizes: 0.5B, 1.5B, 7B, 57B-14B (MoE), 72B trained on data in 29 languages. Qwen2-72B outperforms Llama-3-70B and surpasses the performance of its predecessor, Qwen1.5-110B, despite having fewer parameters. Released under Apache 2.0 except 72B version that still uses the original Qianwen License [Details].
  2. China’s Kuaishou Technology unveiled its text-to-video model Kling that can generate 1080p high-definition videos lasting up to 2 minutes. The model is capable of producing large-scale realistic motions and simulating physical world characteristics [Details Demo videos].
  3. Stability AI released Stable Audio Open, an open source text-to-audio model for generating up to 47 seconds of audio samples and sound effects. It can generate drum beats, instrument riffs, ambient sounds, foley recordings and other audio samples for music production and sound design [Details].
  4. Researchers have used AI to identify nearly one million potential antibiotic compounds from microbial genetic data, marking a significant breakthrough in combating drug-resistant superbugs. Discovering a new antibiotic using conventional methods typically takes about 10 to 15 years [Details].
  5. Udio has added ‘audio uploads’, a new experimental feature to their AI music generation tool. You can upload an audio clip of your choice, and extend this clip either forward or backward by 32 seconds using up to 2 minutes of context [Details].
  6. Two authors of the Stanford Llama3-V team apologized to the Chinese team behind the MiniCPM-Llama3-V 2.5 open-source model, announcing they would withdraw the Llama3-V model from use amidst allegations of plagiarism on social media [Details].
  7. Nvidia shared demo of Project G-Assist - an RTX-powered AI assistant that provides context-aware help for PC games and apps. In addition to in-game assistance, it can share useful system information, configure settings to increase performance and power efficiency, and more [Video Link].
  8. Meta AI researchers introduced No Language Left Behind (NLLB), a single massively multilingual model capable of delivering high-quality translations directly between 200 languages, including the low-resource languages [Details].
  9. Nomic AI released Nomic-Embed-Vision, an open vision embedding model. Any vector created using Nomic-Embed-Text can be used to query vectors created by Nomic-Embed-Vision, and vice versa. The unified multimodal latent space outperforms the modality specific latent spaces of models like OpenAI Clip and OpenAI Text Embedding 3 Small, and making it the first open weights model to do so [Details].
  10. Mistral AI announced Mistral AI fine-tuning API as well as an open-source fine-tuning SDK for Mistral models [Details].
  11. Eleven Labs launched Text to Sound Effects tool. Their new AI Audio model can generate sound effects, short instrumental tracks and soundscapes from a text prompt [Details].
  12. Artificial Analysis launched Artificial Analysis Text to Image Model Leaderboard, to compare the quality of image models. You can take part in the Text to Image Arena, and get your personalized model ranking after 30 votes [Details]
  13. SkyworkAI released Skywork-MoE, a mixture-of-experts (MoE) model with 146 billion parameters, 16 experts, and 22 billion activated parameters. This model is initialized from the pre-existing dense Skywork-13B model. Skywork-MoE shows comparable or superior performance to models with more parameters or more activated parameters, such as Grok-1, DBRX, Mistral 8*22, and Deepseek-V2 [Details].
  14. Nvidia and Hugging Face are partnering to simplify generative AI model deployments. The dedicated NIM endpoint spins up cloud instances, fetches Nvidia-optimized models, and enables inference with just a few clicks [Details].
  15. Firefox 130 will introduce an experimental new capability to automatically generate alt-text for images using a fully private on-device AI model. The feature will be available as part of Firefox’s built-in PDF editor [Details].
  16. Microsoft Research introduced Aurora, a large-scale foundation model of the atmosphere trained on over a million hours of diverse weather and climate data. In under a minute, Aurora produces 5-day global air pollution predictions and 10-day high-resolution weather forecasts that outperform state-of-the-art classical simulation tools and the best specialized deep learning models [Details].
  17. Stability AI officially announced the open release date of Stable Diffusion 3 Medium for June 12th. Signup for the wait list here [Link].
  18. OpenAI shared their research work towards understanding the neural activity of language models and released a full suite of autoencoders for GPT-2 small, along with code for using them, and the feature visualizer to get a sense of what the GPT-2 and GPT-4 features may correspond to [Details]
  19. Together AI released Dragonfly, a set of vision-language models based on a new architecture that enhances fine-grained visual understanding and reasoning about image regions. Two new open-source models released: Llama-3-8b-Dragonfly-v1 a general-domain model trained on 5.5 million image-instruction pairs and Llama-3-8b-Dragonfly-Med-v1 finetuned on additional 1.4 biomedical image-instruction data [Details].
  20. Mamba 2, the next version of Mamba state space model has been released. Researchers shared the new architecture details in this blog post [GitHub].
  21. Mozilla has launched the 2024 Builders Accelerator offering up to $100,000 in funding for projects that advance open source AI, with a focus on Local AI solutions [Details].
  22. Current and former employees of major AI companies have published an open letter ‘A Right to Warn about Advanced Artificial Intelligence’, advocating for stronger protections and transparency measures to enable safe disclosure of AI-related risks without fear of retaliation [Details]
  23. Google updated its AI Overviews in Search, addressing issues with erroneous and fake information [Details].
  24. Amazon’s Project PI, or ‘Private Investigator,’ setup combines generative AI and computer vision to ‘see’ damage on products or determine if they are the wrong color or size before the item gets sent to customers [Details].
  25. Nvidia CEO Jensen Huang introduced the company's next-generation AI-accelerating GPU platform, “Rubin“ expected in 2026 [Details].
Source: AI Brews - Links removed from this post due to auto-delete, but they are present in the newsletter. it's free to join, sent only once a week with bite-sized news, learning resources and selected tools. Thanks!
submitted by wyem to ChatGPTCoding [link] [comments]


2024.06.07 16:50 onlymildlyamused Dealer paid off loan and repo'd the car

Hi all, I'm an attorney but this is not my area of expertise and I'd like to help my friend as best I can. As such here are the facts she's told me:
My friend put 10k down on a new Dodge Durango and got a lease agreement through the dealership with Chase Bank. She was making payments regularly with no problems. One day she gets a letter in the mail from Chase stating that the entire balance was paid, congratulations, etc. She did not make the payoff payment, apparently the dealership did. The dealership then after a few weeks repossessed the car.
Help me help her by understanding what happened? I was under the impression that a contract for a financed vehicle exists between the bank and the car owner, my friend, and that the dealership is out of the equation and does not have any interest after the papers are signed and the car leaves the lot. Which would make payoff by the dealership a gift, instilling no possessory rights in the car, am I wrong?
submitted by onlymildlyamused to legaladvice [link] [comments]


2024.06.07 16:27 campfiresvt Need help with writing cover letter

Im trying to submit my very first proposal on upwork. I work as auditor so i am familiar with doing accounting records or bookkeeping. the job that i applied is to prepare financial statements which i know how to do. i read a lot of tips to write cover letter to attach portfolio or samples that i have done before, but i dont have any. should i mention in my cover letter that i am new in freelancing and i dont have any portfolios or sample works yet?
submitted by campfiresvt to Upwork [link] [comments]


2024.06.07 16:15 Danchuuu- Finding percentage for a bunch of multiple choice answers.

Hi, all. I'm not exactly sure how to word this, so I'll try my best! Sorry in advance!
I have the answer results for 50 students and 30 multiple-choice questions. Here's a sample.
I want to calculate the percentage for each student's answer per answer key (see example below). Each letter answer has a certain percentage. How would I do that for multiple students at once for each question?
Example: A = 10% B = 25% C = 25% D = 40%
Thanks in advance for any help.
submitted by Danchuuu- to excel [link] [comments]


2024.06.07 16:08 BeautifulTart2 Can someone please take me the full process of how an internal audit is done in the Big 4 banks here in Canada?

I want to understand everything end to end.
Audit planning - Where does this start ? So exactly what do they do ?
Fieldwork: - audit will complete their own RCM leveraging business processes and identifying gaps - assess each control for control design effectiveness - develop audit procedures to test operating effectiveness - select a sample - perform the testing
Reporting: - Draft list of audit findings - Get the management comments - load audit findings into the system - draft audit report
submitted by BeautifulTart2 to InternalAudit [link] [comments]


2024.06.07 16:06 TelephoneComplete736 I might have a crush on my recruiter

Listen, I’ve never dated a coworker or ever thought of it but this recruiter just caught my attention without doing anything.
It started off with him just emailing me then calling me to congratulate getting the job. After that he messaged me on WA to ask if I did get the offer letter, I did, and saw his photo for first time.
But I’m still new and only met him twice since it’s a hybrid work arrangement and office is big. He does look the same irl, cute and super tall and introvert (my type oolala)
Then that’s where I knew I wouldn’t mind dating him when I coincidentally found his page on a dating app. I couldn’t believe he’s single like wtf but that alarmed my bell lmao, and he’s 29 already I would expect him to be taken idk
Plus, I’m most probably leaving the job this month to temporarily live overseas but I wouldn’t mind a date with him to get to know his personality but of course I’m too shy. Our company policy in dating coworkers is fine but you always have to keep everything private of course.
What do you reckon I should do
submitted by TelephoneComplete736 to work [link] [comments]


2024.06.07 16:05 unihelp21 WESTERN ACCEPTANCE

WESTERN ACCEPTANCE
aghhhhh just got off the waitlist for main site nursing!!!!
submitted by unihelp21 to OntarioGrade12s [link] [comments]


2024.06.07 15:39 Fresh_Variation8954 No liability letter

Anyone has a recent sample/template of a no liability letter from coop bank? anione pm please.
submitted by Fresh_Variation8954 to Kenya [link] [comments]


2024.06.07 15:15 Lumpy_Care_7058 I feel like I got scammed today.

I feel like I got scammed today.
I feel like I got scammed today because I was in Noida Sector-2 today for the interview for the post of data entry on the name of Amazon but now I think it was all fake. Do anyone here recognizes receipts/offer letters like these because I got scammed today and I feel like crying rn😭
So yesterday I got a call of Vinay Kumar who talked to me so politely and directly talked to me about the salary and incentives that I'm gonna provide you 20k. I was kinda okay in it and got really happy.
Today I went for interview and there were number of people for this post and I feel like they were making a fool because they asked for money and they did it so good I got manipulated idk how they were like there's gonna be a salary account in HDFC and you've to maintain 6600 or atleast 1800 and I like a fool paid it to them directly they were even asking for more I'm glad i didn't have more thinking I'm gonna get this job and this money will come back to me only.
After I came home none of my known or senior has approved me of this I feel like such a fool I feel like crying because this was the only money I had and 1800 is a huge amount for me😭
Do anyone here recognizes receipts/offer letters like these because I really need help right now I'm really tensed also freshers like me please be aware.I even included my family in this my mom even congratulated me when I got home I'm literally crying rn please help😭
If anyone in case knows something about this please let me know I'm highly tensed right now and in need of help please🙏
submitted by Lumpy_Care_7058 to delhiuniversity [link] [comments]


http://activeproperty.pl/